Abstract
About 5-10 % patients scheduled for coronary artery stenting require oral anticoagulation (OAC) for coexisting indications such as atrial fibrillation. Addition of DAPT to OAC (triple anticoagulant therapy) increases bleeding risk. However, there are no studies evaluating bleeding risk using triple
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
